The American Society for Aesthetic Plastic Surgery’s annual meeting in Las Vegas was the venue for discussions on the growing number of new techniques and devices for surgical and nonsurgical cosmetic enhancement.
Interest in these emerging technologies was so popular this year that, for the first time, the society hosted two Hot Topics seminars. The new International Hot Topics program consisted of speakers from outside the United States who discussed products and procedures available only overseas.
“Presentations at the annual Hot Topics seminar focus on the most promising innovations in aesthetic surgery,” said Ohio plastic surgeon Bahman Guyuron, MD, president of the Aesthetic Surgery Education and Research Foundation (ASERF), co-sponsor of Hot Topics with the American Society of Plastic Surgery (ASPS). “Some of these techniques and devices have been in use outside the United States and may be beneficial, but others have little science behind them. So it’s important for people to understand that some may not stand the test of time.”
Highly anticipated panel “Botulinum Toxins-Now There are Three,” featured presentations on the newest advancements in Botulinum Toxin. Michael Kane, MD, of New York, talked about a topical, non-injectable, form of Botulinum Toxin developed by Revance Therapeutics called Topical Toxin. Brian Kinney, MD, of California, presented data of a blind study of PurTox, a form of Botulinum Toxin currently in development by Johnson & Johnson. New York plastic surgeon Z. Paul Lorenc discussed dosing of Reloxin, an injectable form of Botulinum Toxin currently under consideration for approval by the US Food and Drug Administration.
[Source: Original press release]